Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 7,735 | 668 | 7,005 |
| Samples | 703 | 108 | 587 |
| Peptides | 595 | 88 | 519 |
Function
FGFR2 · Fibroblast growth factor receptor 2
The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member is a high-affinity receptor for acidic, basic and/or keratinocyte growth factor, depending on the isoform. Mutations in this gene are associated with Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis. Multiple alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jan 2009].
Isoforms & Proteins
15 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000358487 | P21802 | 730 | 426 |
| ENST00000457416 | P21802-3 | 670 | 410 |
| ENST00000346997 | P21802-5 | 662 | 403 |
| ENST00000369056 | P21802-17 | 622 | 374 |
| ENST00000613048 | D2CGD1* | 612 | 357 |
| ENST00000356226 | P21802-20 | 610 | 354 |
| ENST00000369059 | E7EVR7* | 601 | 349 |
| ENST00000357555 | P21802-21 | 593 | 333 |
| ENST00000360144 | P21802-22 | 575 | 331 |
| ENST00000369060 | P21802-15 | 559 | 345 |
| ENST00000369061 | P21802-23 | 541 | 349 |
| ENST00000478859 | S4R381* | 505 | 290 |
| ENST00000351936 | P21802-5 | 271 | 161 |
| ENST00000359354 | P21802-14 | 157 | 113 |
| ENST00000611527 | A0A087X2D1* | 27 | 20 |
Gene Properties
Recurrent Mutations
All 425 amino-acid changes on canonical ENST00000358487 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in FGFR2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in FGFR2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 12/42 29% | 76/612 12% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 8/133 6% |
| Melanoma | 16/210 8% | 95/1899 5% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Germ Cell Tumour | 0/25 0% | 5/169 3% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Non-Small Cell Lung Carcinoma | 15/304 5% | 25/1390 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Biliary Tract Carcinoma | 3/54 6% | 19/950 2% |
| Colorectal Carcinoma | 16/143 11% | 54/3239 2% |
| Cervical Carcinoma | 0/35 0% | 9/422 2% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 15/810 2% |
| Gastric Carcinoma | 2/74 3% | 34/1809 2% |
| Bladder Carcinoma | 0/58 0% | 19/956 2% |
| Other Sarcomas | 8/69 12% | 3/699 0% |
| Other Solid Cancers | 4/94 4% | 19/1515 1% |
| Hepatocellular Carcinoma | 0/46 0% | 31/2210 1% |
| Ovarian Carcinoma | 2/109 2% | 13/998 1% |
| Breast Carcinoma | 7/144 5% | 37/3264 1% |
| Non-Cancerous | 1/104 1% | 10/830 1% |
| Plasma Cell Myeloma | 0/44 0% | 4/305 1% |
| Head and Neck Carcinoma | 2/85 2% | 17/1574 1% |
| Esophageal Carcinoma | 0/23 0% | 9/769 1% |
| Osteosarcoma | 1/45 2% | 1/166 1% |
| Glioma | 2/52 4% | 15/2127 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Neuroendocrine Tumour | 1/154 1% | 4/577 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 10/1592 1% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 15/2550 1% |
| Other Blood Cancers | 1/61 2% | 14/2725 1% |
Mutation Distribution
Where FGFR2 is mutated · all tissues, split by cell line vs tissue
How many mutations in FGFR2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 7,735 mutations in FGFR2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|